GLP1R and Alzheimer disease: In the sensitivity analysis using a GWAS dataset comprising 71,880 AD/AD-by-proxy cases (eFigure 2, links.lww.com/WNL/C91), genetic variation in the targets of sulfonylureas and GLP-1 analogues showed protective effects (sulfonylureas: OR = 0.78, 95% CI 0.58–1.05; GLP-1 analogues: OR = 0.53, 95% CI 0.37–0.77), although the effect sizes attenuated toward the null possibly because of the dilution effects by AD-by-proxy cases.